BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 29939876)

  • 21. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.
    Lee CI; Menzies AM; Haydu LE; Azer M; Clements A; Kefford RF; Long GV
    Melanoma Res; 2014 Oct; 24(5):468-74. PubMed ID: 25054915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
    Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
    Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
    Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
    J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
    Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
    J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
    Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
    J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.
    Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; Prat A; Arance A
    Clin Transl Oncol; 2017 Jan; 19(1):119-124. PubMed ID: 27147251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
    Zia Y; Chen L; Daud A
    Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.
    Atkinson V; Long GV; Menzies AM; McArthur G; Carlino MS; Millward M; Roberts-Thomson R; Brady B; Kefford R; Haydon A; Cebon J
    Asia Pac J Clin Oncol; 2016 Dec; 12 Suppl 7():5-12. PubMed ID: 27905182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.
    Michalarea V; Fontana E; Garces AI; Williams A; Smyth EC; Picchia S; Rao S; Chau I; Cunningham D; Bali MA
    Curr Probl Cancer; 2019 Oct; 43(5):487-494. PubMed ID: 30827742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
    Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
    Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab].
    Delaitre L; Martins-Héricher J; Truchot E; Denis D; Prophette B; Maillard H; Bénéton-Benhard N
    Ann Dermatol Venereol; 2020 Apr; 147(4):279-284. PubMed ID: 31879092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
    Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
    Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
    Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks of different skin tumour combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population-based cohorts: 1989-2009.
    van der Leest RJT; Hollestein LM; Liu L; Nijsten T; de Vries E
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):382-389. PubMed ID: 28898461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
    Ribero S; Malavenda O; Fava P; Astrua C; Marra E; Osella-Abate S; Sanlorenzo M; Caliendo V; Fierro MT; Quaglino P
    Future Oncol; 2019 Jan; 15(2):133-139. PubMed ID: 30196713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
    Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
    Donia M; Ellebaek E; Øllegaard TH; Duval L; Aaby JB; Hoejberg L; Køhler UH; Schmidt H; Bastholt L; Svane IM
    Eur J Cancer; 2019 Feb; 108():25-32. PubMed ID: 30605822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the PD-1 pathway: a promising future for the treatment of melanoma.
    Mamalis A; Garcha M; Jagdeo J
    Arch Dermatol Res; 2014 Aug; 306(6):511-9. PubMed ID: 24615548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.